ClinicalTrials.gg
Active, not recruitingNCT05879055Updated Jul 9, 2026

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

A Phase 2 interventional study of PM8002 and FOLFIRI in Neuroendocrine Neoplasm, sponsored by Biotheus Inc.. Active, not recruiting at 13 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Biotheus Inc. (part of BioNTech SE) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies in Neuroendocrine Tumors with a site in China — 23 open to participants now, 29 under way, 2 of them phase 3. Neuroendocrine Tumors · China.

Enrollment
37th of 48
31 · median 65
Started
2023
with 3 others
Phase 2
14 of 63
4 open now
Primary completion
2027-01
later than 17 of 28 live
Registered
43rd of 63
by date

Among the 63 studies in Neuroendocrine Tumors with a site in China, this one is the 37th largest by enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2023, is one of 14 in phase 2, reaches primary completion later than 17 of the 28 other live ones, and was the 43rd registered.

Neuroendocrine Tumors

543 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

23 of the 63 studies in Neuroendocrine Tumors with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Neuroendocrine Tumors with a site in China, or all of them as a file.
02

Study summary

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with FOLFIRI as second line treatment for neuroendocrine neoplasm (NEC and Ki-67≥55% G3 NET).

Read the detailed description

This is a phase II, single arm study assessing the efficacy and safety of PM8002 in combination with FOLFIRI as second line treatment for neuroendocrine neoplasm (NEC and Ki-67≥55% G3 NET) who failed first-line platinum-based chemotherapy

03

Conditions studied

  • Neuroendocrine Neoplasm

Browse trials for

Keywords

  • Second line
  • NEC
  • G3 NET
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed form before any trial-related processes;
  2. Aged ≥ 18 years;
  3. Ki-67≥55% G3 NET and NEC were confirmed histologically or cytologically by pathological diagnosis in this study;
  4. Subjects failed platinum-based chemotherapy;
  5. Adequate organ function;
  6. The Eastern Cancer Cooperative Group () performance score of 0 or 1;
  7. Expected survival ≥ 12 weeks;
  8. Had at least one measurable tumor lesion according to v1.1;

Exclusion criteria

Exclusion Criteria:

  1. History of severe allergic disease, severe drug allergy or have known allergy to any component of the study drugs;
  2. Evidence and history of severe bleeding tendency;
  3. History of severe cardiovascular diseases within 6 months;
  4. Subjects should provide formalin-fixed-paraffin-embedded (FFPE) tumor samples during the screening period (up to 24 months);
  5. Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;
  6. History of hematopoietic stem cell transplantation or allogeneic organ transplantation;
  7. History of alcohol abuse, psychotropic substance abuse or drug abuse;
  8. (HIV) infection or known acquired immunodeficiency syndrome;
  9. Pregnant or lactating women;
  10. Other conditions considered unsuitable for this study by the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    PM8002+FOLFIRI

    Subjects will be administered with PM8002 plus FOLFIRI via intravenously (IV) Q2W until disease progression or intolerable toxicity for a maximum of 2 years.

    Drug: PM8002 · Drug: FOLFIRI

Interventions

  • DrugPM8002

    IV infusion

  • DrugFOLFIRI

    IV infusion

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1

    Time frame: Up to approximately 2 years

  2. Treatment related adverse events (TRAEs)

    The incidence and severity of TRAEs graded according to NCI-CTCAE v5.0

    Time frame: Up to 30 days after last treatment

Secondary outcomes

  1. Disease control rate (DCR)

    DCR is defined as the proportion of subjects with CR, PR, or stable disease(SD) based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  2. Duration of response (DoR)

    DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST v1.1) or death due to any cause, whichever occurs first

    Time frame: Up to approximately 2 years

  3. Progression free survival (PFS)

    PFS is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST v1.1)

    Time frame: Up to approximately 2 years

  4. Overall survival (OS)

    OS is the time from the date of first dosing date to death due to any cause.

    Time frame: Up to approximately 2 years

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: Yes — The data will be published or presented for publications (poster, abstract,articles or papers) or any presentations.

Time frame: After the trial completed.

Access criteria: NCI is committed to sharing data in accordance with NIH policy.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jan 2027, 43 months after the start.

Of 98 phase 2 interventional studies under Neuroendocrine Tumors, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 88. This study's planned 43 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2023
First posted
May 30, 2023
StartActual
May 17, 2023
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05879055
Lead sponsor
Biotheus Inc.
Responsible party
Sponsor
First posted
May 30, 2023
Start date
May 17, 2023
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Jul 9, 2026

Study contacts

Jianming Xu
principal investigator · Chinese PLA General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion